{"name":"Ipsen SA","slug":"ipsen","ticker":"IPSEY","exchange":"OTC","domain":"ipsen.com","description":"Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the ","hq":"Paris, France","founded":1964,"employees":"5535","ceo":"David Loew","sector":"Specialty Pharma","stockPrice":48.54,"stockChange":0,"stockChangePercent":0,"marketCap":"$16.0B","metrics":{"revenue":3929200128,"revenueGrowth":9.3,"grossMargin":80.9,"rdSpend":0,"netIncome":443500000,"cash":1526499968,"dividendYield":0.82,"peRatio":31.7,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Somatuline Depot","genericName":"LANREOTIDE","slug":"lanreotide","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":85.7},{"name":"Sohonos","genericName":"PALOVAROTENE","slug":"palovarotene","revenue":200000000,"yoyGrowth":0,"percentOfTotal":14.3}],"timeline":[{"date":"2005-01-01","label":"Increlex first approved","drug":"Increlex","drugSlug":"mecasermin","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Somatuline Depot first approved","drug":"Somatuline Depot","drugSlug":"lanreotide","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Bylvay first approved","drug":"Bylvay","drugSlug":"odevixibat","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Sohonos first approved","drug":"Sohonos","drugSlug":"palovarotene","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Iqirvo first approved","drug":"Iqirvo","drugSlug":"elafibranor","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-01","label":"Iqirvo PHASE3 readout","drug":"Iqirvo","drugSlug":"elafibranor","type":"phase3_readout","sentiment":"neutral"},{"date":"2025-06-01","label":"Decapeptyl patent cliff ($1.3B at risk)","drug":"Decapeptyl","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Zoladex patent cliff ($1.1B at risk)","drug":"Zoladex","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"OnaBoNT-A patent cliff ($1.5B at risk)","drug":"OnaBoNT-A","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":1200000000,"percentOfTotal":85.7,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Somatuline Depot","genericName":"LANREOTIDE","slug":"lanreotide","indication":"Acromegaly","status":"marketed","revenue":1200000000},{"name":"Lanreotide microparticles","genericName":"Lanreotide microparticles","slug":"lanreotide-microparticles","indication":"Acromegaly","status":"phase_3"},{"name":"Triptorelin Pamoate PR 3-month","genericName":"Triptorelin Pamoate PR 3-month","slug":"triptorelin-pamoate-pr-3-month","indication":"Prostate cancer","status":"phase_3"},{"name":"IPN10200","genericName":"IPN10200","slug":"ipn10200","indication":"Neuroendocrine tumors","status":"phase_3"},{"name":"MM-398","genericName":"MM-398","slug":"mm-398","indication":"Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin)","status":"phase_3"},{"name":"Triptorelin (I.N.N.)","genericName":"Triptorelin (I.N.N.)","slug":"triptorelin-i-n-n","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"Triptorelin Acetate PR 1-month","genericName":"Triptorelin Acetate PR 1-month","slug":"triptorelin-acetate-pr-1-month","indication":"Advanced prostate cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":200000000,"percentOfTotal":14.3,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"Sohonos","genericName":"PALOVAROTENE","slug":"palovarotene","indication":"Progressive myositis ossificans","status":"marketed","revenue":200000000},{"name":"BLI800","genericName":"BLI800","slug":"bli800","indication":"Other","status":"marketed"},{"name":"Diosmectite (Smecta®)","genericName":"Diosmectite (Smecta®)","slug":"diosmectite-smecta","indication":"Acute diarrhea in adults and children","status":"marketed"},{"name":"Eziclen®/Izinova®","genericName":"Eziclen®/Izinova®","slug":"eziclen-izinova","indication":"Bowel cleansing prior to colonoscopy or other lower gastrointestinal endoscopic procedures","status":"phase_3"},{"name":"Smecta","genericName":"Smecta","slug":"smecta","indication":"Other","status":"marketed"},{"name":"Tigan®","genericName":"Tigan®","slug":"tigan","indication":"Nausea and vomiting","status":"marketed"},{"name":"EGb 761® (Tanakan®)","genericName":"EGb 761® (Tanakan®)","slug":"egb-761-tanakan","indication":"Age-related cognitive decline and dementia","status":"marketed"},{"name":"Eziclen","genericName":"Eziclen","slug":"eziclen","indication":"Other","status":"phase_3"},{"name":"Fortrans®","genericName":"Fortrans®","slug":"fortrans","indication":"Bowel cleansing prior to colonoscopy or other gastrointestinal procedures","status":"phase_3"},{"name":"IPN01194","genericName":"IPN01194","slug":"ipn01194","indication":"Other","status":"phase_1"},{"name":"IPN10200 dose B","genericName":"IPN10200 dose B","slug":"ipn10200-dose-b","indication":"Other","status":"phase_2"},{"name":"Increlex","genericName":"MECASERMIN","slug":"mecasermin","indication":"Laron-type isolated somatotropin defect","status":"marketed"},{"name":"Iqirvo","genericName":"ELAFIBRANOR","slug":"elafibranor","indication":"Primary biliary cholangitis (PBC)","status":"marketed"},{"name":"OnaBoNT-A","genericName":"OnaBoNT-A","slug":"onabont-a","indication":"Other","status":"marketed"},{"name":"PEG 4000 (Forlax®)","genericName":"PEG 4000 (Forlax®)","slug":"peg-4000-forlax","indication":"Constipation","status":"marketed"},{"name":"Triptorelin embonate 22.5 mg","genericName":"Triptorelin embonate 22.5 mg","slug":"triptorelin-embonate-22-5-mg","indication":"Other","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"AboBoNT-A","genericName":"AboBoNT-A","slug":"abobont-a","indication":"Cervical dystonia","status":"marketed"},{"name":"EGb761","genericName":"EGb761","slug":"egb761","indication":"Age-related cognitive decline","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Bylvay","genericName":"ODEVIXIBAT","slug":"odevixibat","indication":"Pruritus in progressive familial intrahepatic cholestasis (PFIC)","status":"marketed"}]}],"pipeline":[{"name":"Somatuline Depot","genericName":"LANREOTIDE","slug":"lanreotide","phase":"marketed","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone.","indications":["Acromegaly","GEP-NETs","Carcinoid Syndrome"],"catalyst":""},{"name":"Sohonos","genericName":"PALOVAROTENE","slug":"palovarotene","phase":"marketed","mechanism":"Sohonos works by blocking the activity of a specific receptor that helps control bone growth.","indications":["Progressive myositis ossificans"],"catalyst":""},{"name":"AboBoNT-A","genericName":"AboBoNT-A","slug":"abobont-a","phase":"marketed","mechanism":"AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Spasticity","Chronic migraine"],"catalyst":""},{"name":"BLI800","genericName":"BLI800","slug":"bli800","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bylvay","genericName":"ODEVIXIBAT","slug":"odevixibat","phase":"marketed","mechanism":"Bylvay works by blocking the ileal sodium/bile acid cotransporter, a protein that helps reabsorb bile acids in the intestines.","indications":["Pruritus in progressive familial intrahepatic cholestasis (PFIC)"],"catalyst":""},{"name":"Diosmectite (Smecta®)","genericName":"Diosmectite (Smecta®)","slug":"diosmectite-smecta","phase":"marketed","mechanism":"Diosmectite is a natural aluminosilicate clay that absorbs water and toxins in the gastrointestinal tract to reduce diarrhea and protect the intestinal mucosa.","indications":["Acute diarrhea in adults and children","Chronic diarrhea","Diarrhea associated with irritable bowel syndrome"],"catalyst":""},{"name":"EGb761","genericName":"EGb761","slug":"egb761","phase":"phase_3","mechanism":"EGb761 is a standardized Ginkgo biloba extract that enhances cerebral blood flow and provides neuroprotection through antioxidant and anti-inflammatory mechanisms.","indications":["Age-related cognitive decline","Dementia (including Alzheimer's disease)","Cerebrovascular insufficiency","Tinnitus"],"catalyst":""},{"name":"Eziclen®/Izinova®","genericName":"Eziclen®/Izinova®","slug":"eziclen-izinova","phase":"phase_3","mechanism":"Eziclen is a bowel cleansing agent that works as an osmotic laxative to prepare the colon for endoscopic procedures.","indications":["Bowel cleansing prior to colonoscopy or other lower gastrointestinal endoscopic procedures"],"catalyst":""},{"name":"Lanreotide microparticles","genericName":"Lanreotide microparticles","slug":"lanreotide-microparticles","phase":"phase_3","mechanism":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","indications":["Acromegaly","Neuroendocrine tumors (gastroenteropancreatic and thoracic)","Carcinoid syndrome"],"catalyst":""},{"name":"Smecta","genericName":"Smecta","slug":"smecta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tigan®","genericName":"Tigan®","slug":"tigan","phase":"marketed","mechanism":"Tigan (trimethobenzamide) blocks dopamine receptors in the chemoreceptor trigger zone to prevent nausea and vomiting.","indications":["Nausea and vomiting","Postoperative nausea and vomiting"],"catalyst":""},{"name":"Triptorelin Pamoate PR 3-month","genericName":"Triptorelin Pamoate PR 3-month","slug":"triptorelin-pamoate-pr-3-month","phase":"phase_3","mechanism":"Triptorelin Pamoate PR 3-month is a gonadotropin-releasing hormone (GnRH) agonist that works by mimicking the action of the natural hormone GnRH, leading to a decrease in sex hormone production.","indications":["Prostate cancer","Premature puberty"],"catalyst":""},{"name":"EGb 761® (Tanakan®)","genericName":"EGb 761® (Tanakan®)","slug":"egb-761-tanakan","phase":"marketed","mechanism":"EGb 761 is a standardized Ginkgo biloba extract that improves blood flow and reduces oxidative stress in the brain and peripheral tissues.","indications":["Age-related cognitive decline and dementia","Peripheral arterial occlusive disease (claudication)","Tinnitus and vertigo"],"catalyst":""},{"name":"Eziclen","genericName":"Eziclen","slug":"eziclen","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fortrans®","genericName":"Fortrans®","slug":"fortrans","phase":"phase_3","mechanism":"Fortrans is a polyethylene glycol (PEG)-based osmotic laxative that draws water into the bowel to promote bowel evacuation.","indications":["Bowel cleansing prior to colonoscopy or other gastrointestinal procedures"],"catalyst":""},{"name":"IPN01194","genericName":"IPN01194","slug":"ipn01194","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IPN10200","genericName":"IPN10200","slug":"ipn10200","phase":"phase_3","mechanism":"IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth.","indications":["Neuroendocrine tumors","Acromegaly"],"catalyst":""},{"name":"IPN10200 dose B","genericName":"IPN10200 dose B","slug":"ipn10200-dose-b","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Increlex","genericName":"MECASERMIN","slug":"mecasermin","phase":"marketed","mechanism":"Increlex works by mimicking the action of insulin-like growth factor 1 (IGF-1) to stimulate growth in individuals with Laron syndrome.","indications":["Laron-type isolated somatotropin defect"],"catalyst":""},{"name":"Iqirvo","genericName":"ELAFIBRANOR","slug":"elafibranor","phase":"marketed","mechanism":"Iqirvo works by activating peroxisome proliferator-activated receptors to improve liver function.","indications":["Primary biliary cholangitis (PBC)","Decompensated cirrhosis"],"catalyst":""},{"name":"MM-398","genericName":"MM-398","slug":"mm-398","phase":"phase_3","mechanism":"MM-398 is a liposomal formulation of irinotecan that delivers the topoisomerase I inhibitor directly to tumor cells while reducing systemic toxicity.","indications":["Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin)","Metastatic colorectal cancer"],"catalyst":""},{"name":"OnaBoNT-A","genericName":"OnaBoNT-A","slug":"onabont-a","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PEG 4000 (Forlax®)","genericName":"PEG 4000 (Forlax®)","slug":"peg-4000-forlax","phase":"marketed","mechanism":"PEG 4000 is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements.","indications":["Constipation","Bowel preparation before diagnostic procedures"],"catalyst":""},{"name":"Triptorelin (I.N.N.)","genericName":"Triptorelin (I.N.N.)","slug":"triptorelin-i-n-n","phase":"phase_3","mechanism":"Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Central precocious puberty"],"catalyst":""},{"name":"Triptorelin Acetate PR 1-month","genericName":"Triptorelin Acetate PR 1-month","slug":"triptorelin-acetate-pr-1-month","phase":"phase_3","mechanism":"Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Central precocious puberty"],"catalyst":""},{"name":"Triptorelin embonate 22.5 mg","genericName":"Triptorelin embonate 22.5 mg","slug":"triptorelin-embonate-22-5-mg","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2022-02-17","type":"earnings","headline":"Ipsen SA Reports 2021 Full-Year Results","summary":"Ipsen SA reported its 2021 full-year results, with revenue of €3.4 billion and a net income of €1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2021-06-15","type":"deal","headline":"Ipsen SA Acquires 100% of the Shares of RaQualia Pharma Inc.","summary":"Ipsen SA acquired 100% of the shares of RaQualia Pharma Inc., a Japanese biotech company, for approximately €1.1 billion.","drugName":"","sentiment":"positive"},{"date":"2020-05-29","type":"regulatory","headline":"FDA Approves Ipsen's Onivyde for Pancreatic Cancer","summary":"The US FDA approved Ipsen's Onivyde (irinotecan liposome injection) for the treatment of pancreatic cancer.","drugName":"Onivyde","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1sZ1NYZExxa1I2WmNGSEVmOEpkcFl2YzdCS2J4dmVDM1dmM1hGWFQzRl8tOF8xcHVpVjhWeVZ4NmotU3E1Y3BySl9JQ3E?oc=5","date":"2026-04-02","type":"pipeline","source":"Meyka","summary":"BioNxt Solutions Inc. (XPHYF) Competitors - Meyka","headline":"BioNxt Solutions Inc. (XPHYF) Competitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE92QWFqaXBWa3NPUUVBZXdjOGEwMy0zQVFFdXRsSVBkMDV1Qi1LWnMtdVEtdHF4THhVWGxMMlU5S0VCUDRTNUwzU2tETnA?oc=5","date":"2026-04-02","type":"pipeline","source":"Meyka","summary":"CuraScientific Corp. (BNOWD) Competitors - Meyka","headline":"CuraScientific Corp. (BNOWD) Competitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOVloyTXhjZ2dMcFhCaUdlclM1eGlnUkRSRTN0eG9BZUo0WUpFVDhRWElKSV9iQmRiZUxhS3pBSUZqbUZRZkN3bHNHZDFTSVBMdzZ3OG1uNnVobzJaZlBRQkhmelFhaHBOUFJYVlRXQjFNdFh5SzF2UlRjcHIxZnlGX3pEQTBsUkdoTi1uTHF4endoWnJyTEl4cjBMMG9zeFBHVzhiUG1PSl9JYWN5SzdlSFREaG5KM1NFWVloSS13?oc=5","date":"2025-12-01","type":"patent","source":"Ipsen","summary":"Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 - Ipsen","headline":"Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5yeHNfd3d5Q01JT3dsQnU2ak44RkwwOFE5UEJZZTBXTkNsVzhobnNIUkJ2NEJaUXBoUFdVenRoSzI1Q3RUalZZYzB0WFduME5tbFdsdQ?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"TKPHF Stock Price, News & Analysis - Stock Titan","headline":"TKPHF Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOd185elA4Q2czLXNyT2V5YTBYRzE5MXpZeFFENWNXOWxzMWVDV2cxNkhyeUIzQ3FYT1U0SkZyWEt3WHhzNVNDM3NZTjdtQXdsR3FpMDk3XzM1VGdsTVBNaGJBa0E5WkhiUWdNWVFzVWZIWWpacmhIMEVjNTJYNVZHeVNDbzNYYkt3WXd6X19LZzVlYnRrRFhjUQ?oc=5","date":"2025-02-13","type":"earnings","source":"Seeking Alpha","summary":"Ipsen S.A. 2024 Q4 - Results - Earnings Call Presentation (OTCMKTS:IPSEY) 2025-02-13 - Seeking Alpha","headline":"Ipsen S.A. 2024 Q4 - Results - Earnings Call Presentation (OTCMKTS:IPSEY) 2025-02-13","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNFRwTlM1dGtwRlJQRGRwZ1dFNTRhUk5OSkFsUlBBTVk1YUdZYnE4ZFFTRFZSM0RGdjBiR1pYWWtSMG43eno2MGVHZ0xpZXRaVGlYME8xWkpLRDRyT3FhMzhQM0w4b1VQbFRyRlNyck80cHZwT3hsMEVJckNRSGptUEZCZjNmMHNiX3ByaHlMdW83bW5seU9yeEluaEhNV1ZtRGx1b3NXQUpkWXNtMGFRSnowWEhBT1ZmUUVjQnZsNy1VeENnaEFxd1ZKWE95bnp1Q1AzS2tyc1pDTlM4Ymh2TGVVRkFLWjc2aG9zRUhMR2NlR3hoVDJNSw?oc=5","date":"2024-12-03","type":"pipeline","source":"Ipsen","summary":"Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology - Ipsen","headline":"Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNanZuN0kycmpORVQ4Y21jbUw4a28ySEI4MHQwRUowWlRSSWVLMXRDVEx4OTVCd2t6WmxsREVrSnRrbEdVc2JmeGZmQWJFNnNlSEczbzY3WGxWaUR5Sm9tbXhsSnBVQndCSUhvTzE3Q2VqZ3dIR0o0Vzc0RlJrM3VXY2hwcG81cG5wYjFHUFRqQlNOQmRw?oc=5","date":"2023-05-31","type":"pipeline","source":"Yahoo Finance UK","summary":"Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 - Yahoo Finance UK","headline":"Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaThLRDNLaWxEdDB1ZXVhMUJuZi12dVREX2JDWmVBWHVUY05ZRWJrbTFoZ1hTRGRTU0RvVGtBbWFoeUhxcHdnbERZb2d6VFE4U1pJdDIyT1pxdVlWeXB3OS1lc19iUUtZNDJvM0dlYU96VkFjc2c0aExhZlZWSnUxWmgweXo1blBqaE1OaVB0SG1ueWtjSmIxa2ItcFhkY3BHajNJUlUybUlJb0diRXd3Z2ZidkEwbk8wSEtCRW9wb3p0cGM?oc=5","date":"2023-03-02","type":"pipeline","source":"Ipsen","summary":"Acquisition of Albireo has been completed | Ipsen Global - Ipsen","headline":"Acquisition of Albireo has been completed | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMVhtVmVmRVBjMENlZmFYc1VlWTduNHoxR2ZiRWZnRFA3M1dXVU50V0NwTGhQbDJiT3o3QzR3c05HZWZBTnI2dnBNVnBhRlg4dWhDX0ZwclFjb2ozZkQ4MV81d2RoTmgyc3RvX1pJZUlXRDBlb3lseGkzLUNVR3FSY3NwM095N0xkRmhOTllRNFpNT1B6Wjc4eVhKYjA2ZkIzc0hyOUQwdHRITmlFQWNWTVZZc0VBYkduUVZrbUV6eTcydFRURjhyYUtBS29CbkFXcmpXYXRTT2pLalVzVU9uQnVDeWg?oc=5","date":"2023-01-09","type":"deal","source":"Ipsen","summary":"Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global - Ipsen","headline":"Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQam1XTFBqLUowNUNrVUxBbW5oYlFHcUFTSXdmcm9wZ0g0dUNReVpwX0ZPVjlwcm4xSDR6N3FGaTcySXpJY0xEZkJoQjFkTnBhNWVDZ21EOTMzRXhpYVlYMlY5eXV6eVRZLUZLODVQNFRJREFkUG9Scm5nS081Q09UeDBHMnNTbVR6T1Vtbk5pdE5IVi1vWjlrb1pOcEgzMWFIbHR2NkZQMUFTT25panVWbVJDQzN0VmM?oc=5","date":"2022-08-05","type":"patent","source":"Ipsen","summary":"Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 - Ipsen","headline":"Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022","sentiment":"neutral"}],"patents":[{"drugName":"Decapeptyl","drugSlug":"triptorelin","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1300000000},{"drugName":"Zoladex","drugSlug":"goserelin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"OnaBoNT-A","drugSlug":"onabotulinumtoxina","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":26,"phaseCounts":{"marketed":13,"phase_3":11,"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sanofi","Novartis","Roche Holding"],"therapeuticFocus":["Oncology","Neurology","Endocrinology"],"financials":null,"yahoo":{"currentPrice":48.54,"previousClose":48.54,"fiftyTwoWeekHigh":48.54,"fiftyTwoWeekLow":25.11,"fiftyTwoWeekRange":"25.11 - 48.54","fiftyDayAverage":44.16,"twoHundredDayAverage":36.54,"beta":0.34,"enterpriseValue":3455857664,"forwardPE":4.3,"priceToBook":0.8,"priceToSales":4.07,"enterpriseToRevenue":0.88,"enterpriseToEbitda":2.58,"pegRatio":1.24,"ebitda":1340099968,"ebitdaMargin":34.1,"freeCashflow":651950016,"operatingCashflow":1138400000,"totalDebt":970400000,"debtToEquity":22.4,"currentRatio":1.96,"returnOnAssets":9.6,"returnOnEquity":10.4,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0.4,"payoutRatio":0.26,"fiveYearAvgDividendYield":1.14,"exDividendDate":1749427200,"insiderHeldPercent":0,"institutionHeldPercent":0,"sharesOutstanding":329624880,"floatShares":26544542,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.53,"epsForward":11.25,"revenuePerShare":11.88,"bookValue":60.73,"officers":[{"age":58,"name":"Mr. David  Loew","title":"MD, CEO & Director"},{"age":56,"name":"Mr. Aymeric  Le Chatelier","title":"Executive VP & CFO"},{"age":null,"name":"Mr. Pierrick  Lefranc","title":"Executive Vice President of Technical Operations"},{"age":41,"name":"Mr. Henry  Wheeler M.Sc.","title":"Global Vice President of Investor Relations"},{"age":null,"name":"Ms. Caroline  Sitbon","title":"Executive VP & General Counsel"},{"age":59,"name":"Mr. Regis  Mulot","title":"Executive VP & Chief Human Resources Officer"},{"age":54,"name":"Ms. Dominique  Bery","title":"Head of Nordics & Baltics"},{"age":null,"name":"Mr. Philippe  Lopes-Fernandes CBO","title":"Executive VP & Chief Business Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.ipsen.com","phone":"33 1 58 33 50 00"}}